LU92596I2 - Vedolizumab et ses variantes thérapeutiquement équivalentes, comme protégées par le brevet de base, notamment vedolizumab - Google Patents

Vedolizumab et ses variantes thérapeutiquement équivalentes, comme protégées par le brevet de base, notamment vedolizumab Download PDF

Info

Publication number
LU92596I2
LU92596I2 LU92596C LU92596C LU92596I2 LU 92596 I2 LU92596 I2 LU 92596I2 LU 92596 C LU92596 C LU 92596C LU 92596 C LU92596 C LU 92596C LU 92596 I2 LU92596 I2 LU 92596I2
Authority
LU
Luxembourg
Prior art keywords
present
immunoglobulin
humanized
vedolizumab
human
Prior art date
Application number
LU92596C
Other languages
English (en)
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24814673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92596(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of LU92596I2 publication Critical patent/LU92596I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU92596C 1996-08-15 2014-11-12 Vedolizumab et ses variantes thérapeutiquement équivalentes, comme protégées par le brevet de base, notamment vedolizumab LU92596I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/700,737 US7147851B1 (en) 1996-08-15 1996-08-15 Humanized immunoglobulin reactive with α4β7 integrin

Publications (1)

Publication Number Publication Date
LU92596I2 true LU92596I2 (fr) 2015-01-12

Family

ID=24814673

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92596C LU92596I2 (fr) 1996-08-15 2014-11-12 Vedolizumab et ses variantes thérapeutiquement équivalentes, comme protégées par le brevet de base, notamment vedolizumab

Country Status (20)

Country Link
US (3) US7147851B1 (fr)
EP (2) EP1710314A1 (fr)
JP (3) JP4171071B2 (fr)
CN (1) CN100406562C (fr)
AT (1) ATE321788T1 (fr)
AU (1) AU730326C (fr)
BE (1) BE2014C068I2 (fr)
BR (1) BRPI9711079B1 (fr)
CA (1) CA2263106C (fr)
DE (1) DE69735596T3 (fr)
DK (1) DK0918797T4 (fr)
ES (1) ES2262186T5 (fr)
HK (1) HK1021822A1 (fr)
IL (3) IL128052A0 (fr)
LT (1) LTC0918797I2 (fr)
LU (1) LU92596I2 (fr)
NZ (1) NZ334226A (fr)
PT (1) PT918797E (fr)
SI (1) SI0918797T2 (fr)
WO (1) WO1998006248A2 (fr)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7090845B2 (en) * 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
AU2011226857B2 (en) * 1998-05-13 2013-09-19 Genentech, Inc. Diagnosis and treatment of hepatic disorders
JP2002530355A (ja) * 1998-11-25 2002-09-17 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 炎症性疾患のための治療剤としてのαＥβ７インテグリンのアンタゴニスト
EE05662B1 (et) * 1999-04-22 2013-06-17 Biogen, Inc. Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine
AU2006220426B2 (en) * 2000-04-14 2008-10-30 Genentech Inc. Method of administering an antibody
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
CA2470643C (fr) * 2001-12-17 2011-10-18 Bryan Paul Morgan Reactifs clivables destines a une administration au foyer de la maladie
JP4460302B2 (ja) 2002-02-05 2010-05-12 ジェネンテック インコーポレイテッド タンパク質精製法
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
WO2004063351A2 (fr) * 2003-01-09 2004-07-29 Macrogenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
BRPI0407058A (pt) * 2003-02-01 2006-01-17 Neuralab Ltd Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento
WO2005016968A2 (fr) 2003-07-28 2005-02-24 Genentech, Inc. Reduction de la lixiviation de la proteine a lors de la chromatographie d'affinite sur la proteine a
CA2536918A1 (fr) 2003-08-26 2005-03-03 Leland Shapiro Compositions et procedes pour molecules de fusion fc de l'alpha-1 antitrypsine
JP2007521248A (ja) 2003-12-10 2007-08-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヒト化抗ｃｃｒ２抗体および該抗体を使用する方法
DK2177537T3 (da) 2004-01-09 2011-12-12 Pfizer Antistoffer til MAdCAM
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
SI1784426T1 (sl) 2004-09-03 2012-03-30 Genentech Inc Humanizirani antagonisti proti beta in njihove uporabe
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2007007160A2 (fr) * 2005-07-11 2007-01-18 Pfizer Limited Anticorps anti-madcam servant a traiter la fievre
WO2007007151A2 (fr) * 2005-07-11 2007-01-18 Pfizer Limited Utilisation d'anticorps anti mad-cam dans le traitement de l'emphyseme
EP1948691A1 (fr) * 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. IMMUNOGLOBULINE HUMANISEE REACTIVE AVEC L INTEGRINE a4ß7
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (fr) * 2007-07-27 2009-02-05 Elan Pharma International Limited Traitement de maladies amyloïdogéniques
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079302A2 (fr) 2006-12-21 2008-07-03 Millipore Corporation Purification de protéines
EP2120915B1 (fr) 2007-01-22 2011-09-28 Genentech, Inc. Précipitation de polyélectrolyte et purification de protéines
JP2010520204A (ja) * 2007-03-02 2010-06-10 アムジェン インコーポレイテッド 腫瘍疾患を治療するための方法および組成物
JP2010521966A (ja) * 2007-03-20 2010-07-01 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリンに結合するヒト化免疫グロブリンをコードする核酸
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN102838673B (zh) 2007-06-25 2016-05-11 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
LT3327026T (lt) 2007-07-09 2019-11-11 Genentech Inc Disulfidinio ryšio redukcijos prevencija rekombinantinių polipeptidų gaminimo metu
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
ES2666170T3 (es) 2007-10-30 2018-05-03 Genentech, Inc. Purificación de anticuerpos mediante cromatografía de intercambio catiónico
PT2243829E (pt) * 2008-01-11 2014-10-24 Astellas Pharma Inc Anticorpo anti-integrina-alfa9 humana humanizado melhorado
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009151514A1 (fr) 2008-06-11 2009-12-17 Millipore Corporation Bioréacteur à cuve agitée
LT2848625T (lt) 2008-08-14 2019-10-10 Genentech, Inc. Priemaišų pašalinimo būdai, panaudojant reziduojančio baltymo pakeitimą jonų mainų membraninės chromatografijos pagalba
CN102209554A (zh) 2008-09-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 用于防止蛋白质氧化降解的组合物和方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102256993A (zh) 2008-12-16 2011-11-23 米利波尔公司 蛋白的纯化
US20100190963A1 (en) 2008-12-16 2010-07-29 Millipore Corporation Stirred Tank Reactor And Method
CN102333548B (zh) 2009-02-27 2013-01-30 健泰科生物技术公司 用于蛋白质标记的方法和组合物
MX2011009897A (es) * 2009-03-20 2011-12-08 Amgen Inc Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
AU2016208453B2 (en) * 2009-03-20 2018-02-22 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
AU2013205341B2 (en) * 2009-03-20 2016-05-05 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
US8617554B2 (en) 2009-05-13 2013-12-31 Genzyme Corporation Anti-human CD52 immunoglobulins
EP3431588A1 (fr) 2009-08-11 2019-01-23 F. Hoffmann-La Roche AG Production de protéines dans des milieux de culture cellulaire sans glutamine
WO2011028753A1 (fr) 2009-09-01 2011-03-10 Genentech, Inc. Purification améliorée d'une protéine grâce à une élution modifiée de la protéine a
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
KR101878369B1 (ko) 2010-03-22 2018-07-16 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
WO2011146394A1 (fr) 2010-05-17 2011-11-24 Millipore Corporation Polymères répondant à des stimuli pour la purification de biomolécules
WO2011150241A2 (fr) 2010-05-28 2011-12-01 Genentech, Inc. Réduction du niveau de lactate et augmentation de la production de polypeptides par régulation négative de l'expression de la lactate déshydrogénase et de la pyruvate déshydrogénase kinase
MY161390A (en) 2010-06-24 2017-04-14 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
EP2603525A1 (fr) 2010-08-13 2013-06-19 F.Hoffmann-La Roche Ag Anticorps anti-il-1 et il-18, pour le traitement de maladies
WO2012030512A1 (fr) 2010-09-03 2012-03-08 Percivia Llc. Procédé de purification de protéine en flux
PE20141672A1 (es) 2011-05-02 2014-11-26 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-alfa4�7
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
AU2012272636A1 (en) 2011-06-24 2013-05-02 Advent Bio Holdings Llc Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EP2794635B8 (fr) 2011-12-22 2018-11-14 H. Hoffnabb-La Roche Ag Chromatographie par échange d'ions sur membrane
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
AU2013202648B2 (en) * 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EA201992881A3 (ru) * 2012-01-12 2020-12-30 Милленниум Фармасьютикалз, Инк. Композиция анти-47 антитела
CN104350156B (zh) 2012-03-27 2019-04-02 弗·哈夫曼-拉罗切有限公司 用于重组蛋白质的改进的收获操作
CN103374073A (zh) * 2012-04-26 2013-10-30 中国科学院上海生命科学研究院 识别活化形式整合素α4β7的人源化单克隆抗体
US20130309226A1 (en) 2012-05-18 2013-11-21 Genentech, Inc. High-concentration monoclonal antibody formulations
US9393327B2 (en) 2012-12-19 2016-07-19 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
EP3777535A1 (fr) 2014-07-09 2021-02-17 F. Hoffmann-La Roche AG Réglage de ph pour améliorer la récupération par décongélation de banques de cellules
MA40592A (fr) 2014-10-06 2016-04-14 Chemocentryx Inc Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
US20170360926A1 (en) 2014-12-24 2017-12-21 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
EP3336184A4 (fr) * 2015-08-11 2019-01-23 Osaka University Anticorps
CA2996716A1 (fr) * 2015-09-04 2017-03-09 The California Institute For Biomedical Research Proteines de fusion immunoglobuline-insuline
WO2017117558A1 (fr) 2015-12-31 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Méthodes et utilisations de l'alpha-1 anti-trypsine, ou de ses formes recombinées, sur une maladie du greffon contre l'hôte, réfractaire aux stéroïdes, impliquant des complications gastro-intestinales
WO2017160699A2 (fr) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Méthode de traitement de la réaction du greffon contre l'hôte (gvd)
KR102667332B1 (ko) * 2016-03-14 2024-05-20 밀레니엄 파머슈티컬스 인코퍼레이티드 이식편대숙주 질환을 치료하거나 예방하는 방법
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
WO2017165742A1 (fr) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Procédés de traitement d'événements indésirables liés à l'immunité gastro-intestinale dans des polythérapies anti-ctla4 et anti-pd-1
CA3019373A1 (fr) 2016-03-29 2017-10-05 Geltor, Inc. Expression de proteines dans des bacteries gram negatif, avec un rapport du volume periplasmique au volume cytoplasmique compris entre 0,5:1 et 10:1
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease
WO2017214376A1 (fr) * 2016-06-10 2017-12-14 Elwha Llc Compositions et procédés comprenant une lignée cellulaire de lymphocytes b exprimant une immunoglobuline membranaire différente d'une immunoglobuline sécrétée et fonction cytolytique
WO2017218434A1 (fr) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Méthode de traitement de maladie intestinale inflammatoire
WO2018104893A1 (fr) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Anticorps anti-alpha4-beta7 présentant une liaison à fcrn et/ou une demi-vie augmentées
CN110049778A (zh) 2016-12-22 2019-07-23 豪夫迈·罗氏有限公司 减少冻干多肽重构时间的方法和制剂
MX2019012749A (es) 2017-04-28 2020-02-03 Millennium Pharm Inc Metodos para tratar trastornos pediatricos.
PE20200616A1 (es) 2017-07-14 2020-03-11 Pfizer ANTICUERPOS CONTRA MAdCAM
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
US20210253996A1 (en) 2018-07-03 2021-08-19 Bristol-Myers Squibb Company Methods of producing recombinant proteins
CN113166695A (zh) 2018-10-10 2021-07-23 勃林格殷格翰国际公司 用于高密度生物反应器培养中的膜气体转移的方法
EP3902834A4 (fr) * 2018-11-30 2022-08-24 Memorial Sloan Kettering Cancer Center Compositions hétérodimeres d'anticorps à spécifiques et à tétravalents, et utilisations de celles-ci
TW202102266A (zh) 2019-04-01 2021-01-16 美商建南德克公司 用於穩定含有蛋白質之配方之組合物及方法
CN113993885A (zh) 2019-04-12 2022-01-28 格尔托公司 重组弹性蛋白及其生产
CN114206383A (zh) * 2019-06-10 2022-03-18 武田药品工业株式会社 用于抗体生产的细胞培养方法和组合物
JP2022543781A (ja) 2019-08-01 2022-10-14 ブリストル－マイヤーズ スクイブ カンパニー フェッドバッチ細胞培養におけるタンパク質産生性の改良方法
KR20230073270A (ko) 2020-09-22 2023-05-25 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 생산 방법
WO2023015234A1 (fr) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Procédés de culture cellulaire pour la production de protéines thérapeutiques
WO2023049687A1 (fr) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Procédés de régulation du taux d'oxygène dissous (do) dans une solution comprenant une protéine recombinante dans un récipient de stockage
WO2023245097A2 (fr) 2022-06-16 2023-12-21 Cephalon Llc Immunoconjugués anticorps anti-pd1-il2 atténuée et leurs utilisations
CN117777292A (zh) * 2023-12-28 2024-03-29 天津大学 抗整合素α4β7纳米抗体及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
DE3852236T2 (de) 1987-08-11 1995-04-06 Univ Leland Stanford Junior Verfahren zur Kontrolle der Leukozyten-Extravasation.
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US5223392A (en) * 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
WO1989007142A1 (fr) 1988-02-05 1989-08-10 Morrison Sherie L Anticorps a region constante a modification de domaine
WO1990007321A2 (fr) 1988-12-23 1990-07-12 The Board Of Trustees Of The Leland Stanford Junior University Sequences de guidage de recepteurs de lymphocytes et leurs emplois
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IL113261A (en) 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Repression by peptides of lymphocyte binding to vascular endothelium by interaction of extracellular uterine capacitor with connective tissue, and pharmaceutical preparations containing
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2204890T3 (es) 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
US5665595A (en) * 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
WO1993015764A1 (fr) 1992-02-12 1993-08-19 Biogen, Inc. Traitement de l'inflammation intestinale
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
WO1994012214A1 (fr) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Anticorps humanises reagissant avec la cd-18
WO1994013312A1 (fr) 1992-12-15 1994-06-23 The Board Of Trustees Of The Leland Stanford Junior University Adressine vasculaire de muqueuses, adn codant ladite adressine et expression de ladite adressine
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
DK0682529T4 (da) 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
CA2163345A1 (fr) 1993-06-16 1994-12-22 Susan Adrienne Morgan Anticorps
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CA2182013C (fr) 1994-01-25 2007-07-17 Mary M. Bendig Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin

Also Published As

Publication number Publication date
IL128052A0 (en) 1999-11-30
IL175570A0 (en) 2006-09-05
JP4578536B2 (ja) 2010-11-10
SI0918797T2 (sl) 2016-01-29
AU730326C (en) 2005-06-16
US7147851B1 (en) 2006-12-12
CN1227607A (zh) 1999-09-01
EP0918797B2 (fr) 2015-09-23
ES2262186T5 (es) 2015-12-11
US20090011464A1 (en) 2009-01-08
CA2263106C (fr) 2010-08-03
BRPI9711079B8 (fr) 2021-05-25
JP2001507210A (ja) 2001-06-05
SI0918797T1 (sl) 2006-10-31
JP2008281562A (ja) 2008-11-20
WO1998006248A3 (fr) 1998-05-07
IL128052A (en) 2006-08-20
DK0918797T3 (da) 2006-07-31
US7402410B2 (en) 2008-07-22
JP4171071B2 (ja) 2008-10-22
ES2262186T3 (es) 2006-11-16
ATE321788T1 (de) 2006-04-15
JP2010246548A (ja) 2010-11-04
NZ334226A (en) 2000-10-27
DE69735596T3 (de) 2016-02-25
WO1998006248A2 (fr) 1998-02-19
HK1021822A1 (en) 2000-07-07
BE2014C068I2 (fr) 2017-09-22
BR9711079A (pt) 2000-06-06
DK0918797T4 (en) 2016-01-11
DE69735596D1 (de) 2006-05-18
LTC0918797I2 (lt) 2017-05-10
EP1710314A1 (fr) 2006-10-11
EP0918797A2 (fr) 1999-06-02
PT918797E (pt) 2006-08-31
EP0918797B1 (fr) 2006-03-29
AU730326B2 (en) 2001-03-01
BRPI9711079B1 (pt) 2017-06-20
DE69735596T2 (de) 2006-12-21
US20060292140A1 (en) 2006-12-28
CA2263106A1 (fr) 1998-02-19
AU3972897A (en) 1998-03-06
JP5166483B2 (ja) 2013-03-21
CN100406562C (zh) 2008-07-30

Similar Documents

Publication Publication Date Title
LU92596I2 (fr) Vedolizumab et ses variantes thérapeutiquement équivalentes, comme protégées par le brevet de base, notamment vedolizumab
CY1121451T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα κατα του ctla-4
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
BR9507594B1 (pt) anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteìna recombinante.
EA200300233A1 (ru) Получение гуманизированных антител в трансгенных животных
WO1999037681A3 (fr) Procede servant a preparer des fragments d'anticorps
ATE483733T1 (de) Hochaffine humane antikörper gegen tumorantigene
EP0699755A3 (fr) Procédé pour obtenir des immunoglobulines modifiées avec une immunogénicité réduite des domaines variables d'un anticorps murin, compositions les contenant
WO1998033919A3 (fr) Anticorps anti-alpha-v beta-3 humanises de recombinaison, acides nucleiques codant lesdits anticorps et leurs procedes d'utilisation
ATE510854T1 (de) Lineares, schweres antikörperkettenfragment vh- ch1-vh-ch1
BG61095B2 (en) Humanized immunoglobulins, their preperation and application
HUP9802401A2 (hu) Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására
DE69000338D1 (de) Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.
ES2116789T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y empleo.
PT678523E (pt) Anticorpos recombinantes anti-vih e sua preparacao
CA2185112A1 (fr) Anticorps monoclonaux humanises contre l'interleukine-4 chez l'homme
TH13774EX (th) รีคอมบิแนนท์แอนติบอดีสำหรับการรักษาโรคมนุษย์
GR1001050B (el) Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων.